Bimekizumab Treatment Impact on Pain and Fatigue in Patients with Active Psoriatic Arthritis Who Were Biologic DMARD- Naive or Had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3 Studies

被引：0
|
作者：
Husni, M. Elaine [1 ]
Mease, Philip J. [2 ,3 ]
Merola, Joseph [4 ]
Behrens, Frank
Favalli, Ennio G. [5 ,6 ,7 ]
McGonagle, Dennis [8 ]
Tillett, William R. [9 ]
Tsuji, Shigeyoshi [10 ]
Ink, Barbara [11 ]
Bajracharya, Rajan [11 ]
Lambert, Jeremy [12 ]
Coarse, Jason [13 ]
Gossec, Laure [14 ,15 ]
机构：
[1] Cleveland Clin, Dept Rheumat & Immunol Dis, Cleveland, OH USA
[2] Swedish Med Center, Providence St Joseph Hlth, Seattle, WA USA
[3] Univ Washington, Sch Med, Seattle, WA USA
[4] Harvard Med Sch, Brigham & Womens Hosp, Newton, MA USA
[5] Goethe Univ, Univ Hosp, Div Rheumatol, Frankfurt, Germany
[6] Fraunhofer Inst Translat Med Pharmacol, Frankfurt, Germany
[7] Univ Milan, ASST Gaetano Pini CTO, Dept Rheumatol, Milan, Italy
[8] Univ Leeds, Leeds Biomed Res Ctr, Leeds, England
[9] Royal Natl Hosp Rheumat Dis, Dept Rheumatol, Bath, England
[10] Nippon Life Hosp, Osaka, Japan
[11] UCB Pharma, Slough, England
[12] UCB Pharma, Irigny, France
[13] UCB Pharma, Morrisville, NY USA
[14] Sorbonne Univ, Paris, France
[15] Hop La Pitie Salpetriere, Paris, France
来源：
ARTHRITIS & RHEUMATOLOGY | 2023年 / 75卷
关键词：
PHASE-3; TRIAL; DOUBLE-BLIND;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0527
引用
收藏
页码：1035 / 1038
页数：4
相关论文
共 50 条
  • [21] IMPROVED PAIN AND FATIGUE WITH IXEKIZUMAB TREATMENT IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PREVIOUS INADEQUATE RESPONSE TO TNF INHIBITORS: THREE YEAR FOLLOW-UP FROM A PHASE 3 STUDY (SPIRIT-P2)
    Orbai, A. M.
    De Vlam, K.
    Nash, P.
    Birt, J.
    Gallo, G.
    Stenger, K.
    Geneus, V.
    Combe, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 771 - 771
  • [22] Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial
    Deodhar, Atul
    Helliwell, Philip S.
    Boehncke, Wolf-Henning
    Kollmeier, Alexa P.
    Hsia, Elizabeth C.
    Subramanian, Ramanand A.
    Xu, Xie L.
    Sheng, Shihong
    Agarwal, Prasheen
    Zhou, Bei
    Zhuang, Yanli
    Ritchlin, Christopher T.
    LANCET, 2020, 395 (10230): : 1115 - 1125
  • [23] Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF Inhibitors: Two-Year Follow-up from a Phase 3 Study
    Rahman, Proton
    Orbai, Ana-Marie
    Gellett, Amanda
    Kerr, Lisa
    Constantin, Arnaud
    Gladman, Dafna
    JOURNAL OF RHEUMATOLOGY, 2019, 46 (07) : 847 - 848
  • [24] Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF Inhibitors: Two-Year Follow-up from a Phase 3 Study
    Orbai, Ana-Maria
    Gellett, Amanda M.
    Kerr, Lisa
    Constantin, Arnaud
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [25] Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF inhibitors: 52-week Results from a Phase 3 Study
    Genovese, Mark
    Helliwell, Philip
    Combe, Bernard
    Kremer, Joel
    Adams, David
    Lee, Chin
    Kerr, Lisa
    Nash, Peter
    Rahman, Proton
    JOURNAL OF RHEUMATOLOGY, 2018, 45 (07) : 996 - 996
  • [26] Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF Inhibitors: 52-Week Results from a Phase 3 Study
    Genovese, Mark C.
    Combe, Bernard
    Kremer, Joel
    Adams, David
    Lee, Chin
    Kerr, Lisa
    Nash, Peter
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [27] EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PREVIOUS INADEQUATE RESPONSE TO TNF INHIBITORS: 52-WEEK RESULTS FROM A PHASE 3 STUDY
    Genovese, M. C.
    Combe, B.
    Kremer, J.
    Adams, D. H.
    Lee, C.
    Kerr, L.
    Nash, P.
    Garcia, E. G.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S158 - S158
  • [28] EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PREVIOUS INADEQUATE RESPONSE TO TNF INHIBITORS: 52-WEEK RESULTS FROM A PHASE 3 STUDY
    Genovese, M. G.
    Combe, B.
    Kremer, J.
    Adams, D.
    Lee', C.
    Kerr, L.
    Nash, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1035 - 1036
  • [29] Bimekizumab Treatment in Patients with Active PsA and Prior Inadequate Response to TNF Inhibitors: Sustained Efficacy and Safety Results from a Phase 3 Study and Its Open-Label Extension up to 1 Year
    Coates, Laura
    Landewe, Robert B. M.
    McInnes, Iain
    Mease, Philip J.
    Ritchlin, Christopher T.
    Tanaka, Yoshiya
    Asahina, Akihiko
    Behrens, Frank
    Gladman, Dafna
    Gossec, Laure
    Gottlieb, Alice B.
    Warren, Richard B.
    Ink, Barbara
    Bajracharya, Rajan
    Coarse, Jason
    Merola, Joseph
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4401 - 4404
  • [30] Ixekizumab treatment of biologic-naive patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)
    Chandran, Vinod
    van der Heijde, Desiree
    Fleischmann, Roy M.
    Lespessailles, Eric
    Helliwell, Philip S.
    Kameda, Hideto
    Burgos-Vargas, Ruben
    Erickson, Janelle S.
    Rathmann, Suchitrita S.
    Sprabery, Aubrey Trevelin
    Birt, Julie A.
    Shuler, Catherine L.
    Gallo, Gaia
    RHEUMATOLOGY, 2020, 59 (10) : 2774 - 2784
12345